Navigation Links
BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S.
Date:3/17/2009

ATLANTA, March 17 /PRNewswire/ -- Siemens Energy & Automation, Inc. announced today that BIND Biosciences, Inc., Cambridge, Mass., has selected Simatic(R) PCS 7 Lab hardware and software to help its scientists manage pre- and post-clinical experimental data.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )

BIND Biosciences develops targeted therapeutics based upon their novel polymeric nanoparticle drug delivery technology platform. It is the first company in the United States to install the PCS 7 Lab hardware and software.

With startup services provided by system integrator Optimation Technology, Inc., the phased automation implementation will help BIND Biosciences drive process development as well as monitor and control manufacturing operations.

"The flexibility and expandability of the PCS 7 Lab system will allow us to grow economically and efficiently through all three phases of the implementation," said Jeff Hrkach, BIND Biosciences Vice President of Pharmaceutical Sciences. "The system has all the tools we need to collect and manage our data as well as protect our intellectual property."

The PCS 7 Lab configuration, designed for laboratory and process development research and development applications, is based on Siemens Simatic PCS 7 Box. The UL certified system includes a preinstalled rack of I/O modules that can be easily reconfigured to fit any size or type of laboratory environment.

"This partnership with BIND gives Siemens the opportunity to help BIND bring drugs to market faster, " said Glenn Restivo, Siemens Life Sciences Industry Manager. "We adhere to the Design of Experiment and Quality by Design philosophies that build quality into every step of the process - from laboratory experimentation through every phase of manufacturing."

The implementation phase of the PCS 7 project is underway and focuses on basic experimentation and data collection. A second phase is under consideration for cataloging and organizing experimental data. Phase three, also under consideration, will include Siemens Sipat for Process Analytical Technology (PAT), Interspec for specification management and the R&D Suite for Electronic Lab Notebook (ELN).

About Siemens:

Siemens Energy & Automation, Inc. is one of Siemens' operating companies in the U.S. Headquartered in the Atlanta suburb of Alpharetta, Ga., Siemens Energy & Automation, Inc. manufactures and markets one of the world's broadest ranges of electrical and electronic products, systems and services to industrial and construction market customers. Its technologies range from circuit protection and energy management systems to process control, industrial software and totally integrated automation solutions. The company also has expertise in systems integration, technical services and turnkey industrial systems. For more information: www.sea.siemens.com.

Siemens AG (NYSE: SI) is a global powerhouse in electronics and electrical engineering, and operates in the industry, energy and healthcare sectors. For more than 160 years, Siemens has built a reputation for leading-edge innovation and the quality of its products, services and solutions. With 428,000 employees in 190 countries, Siemens reported worldwide sales of $116.6 billion in fiscal 2008. With its U.S. corporate headquarters in New York City, Siemens in the USA reported sales of $22.4 billion and employs approximately 69,000 people throughout all 50 states and Puerto Rico. For more information on Siemens in the United States, visit www.usa.siemens.com.


'/>"/>
SOURCE Siemens Energy & Automation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
6. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
7. Anaptys Biosciences Raises Over $33 Million in Series B Financing
8. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
9. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... ... Love is in the air at King Kullen! The local grocer is ... staple for Valentine’s Day is a must-have, and can be picked up with all ... are long-stem roses available, but also other flower bouquets, elegantly wrapped and ready to ...
(Date:2/5/2016)... ... 05, 2016 , ... The Muscular Dystrophy Association and Sailormen ... the 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise ... related diseases that severely limit strength and mobility. , Now through March ...
(Date:2/5/2016)... Miami, Florida (PRWEB) , ... February 05, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – is poised to once again host, Swirl, A Wine Tasting Event ...
(Date:2/5/2016)... ... ... Give To Cure today announced that it is working with ... Cure’s campaign that is crowdfunding clinical trials to help find cures faster for Alzheimer’s ... smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. , ...
(Date:2/5/2016)... ... , ... Stuart Bentkover, MD, FACS is thrilled to announce the ... effective tattoo removal today, Dr. Bentkover is the only doctor in Central Massachusetts to ... has been approved by the Food and Drug Administration (FDA) as a safe and ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016 ... addition of the "Global Musculoskeletal Partnering ... company profile to their offering. ... addition of the "Global Musculoskeletal Partnering ... company profile to their offering. ...
(Date:2/5/2016)... Dehaier Medical Systems Ltd. (Nasdaq: ... develops, markets and sells medical devices and wearable ... and international markets, today announced its corporate ... the Company,s resources to develop its mobile health ... focus more on its major businesses. As of ...
(Date:2/5/2016)... Site Profile: --> ... The Speech Recognition People, announced their latest primary healthcare case study ... reduce turnaround times and to save the practice money. ... 2013 Challenge: --> ,- Wirral CCG ,- ... Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
Breaking Medicine Technology: